SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

NGEN

NervGen Pharma Corp.
BULLISH
Impact 6/10
Horizonmonths Processed4d 16h ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor enrollment progress and data readouts from the Phase 3 RESTORE study (NCT07799532). Breakthrough Therapy designation increases the likelihood of expedited FDA review but does not guarantee approval; the Phase 3 results will be the key catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

NVG-291

● Neutral Named in this press release
Impact
Phase
Phase 3 (registrational)
Time to market
If Phase 3 RESTORE succeeds, a potential FDA submission could occur in 2028-2029, assuming enrollment completes and the 16-week treatment period yields positive results. Breakthrough Therapy designation may accelerate FDA review.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 RESTORE topline data readout, likely in late 2027 or 2028 given enrollment just began in October 2026. Positive data would validate NVG-291 as a first-in-class neuroreparative therapy for a large unmet need with no approved pharmacologic alternatives; negative data would be devastating for this single-asset company. Interim enrollment updates or any early efficacy signals could also move the stock.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.63
T+0 close · Nov 12, 2026 · via day close
Latest settled
+15.34%
T+1 · $1.88
Vs SPY
+15.70%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.63entry
  2. T+1 · 4d ago +15.34%α +15.70% · $1.88
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NervGen Pharma announced that the FDA granted Breakthrough Therapy designation to NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, based on Phase 1b/2a CONNECT SCI data showing functional hand use improvements. The designation may expedite development and regulatory review, but does not guarantee approval.

Key Facts

  • FDA granted Breakthrough Therapy designation for NVG-291 in chronic traumatic cervical motor-incomplete SCI
  • Designation based on safety and efficacy data from Phase 1b/2a CONNECT SCI study
  • Phase 3 RESTORE registrational study is enrolling, targeting ~150 participants in US and Canada
  • NVG-291 is a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway
  • No serious adverse events or treatment discontinuations in the Phase 1b/2a study
  • Approximately 312,000 people in the US live with traumatic SCI; no FDA-approved pharmacologic therapies for chronic SCI

Financial Impact

Breakthrough Therapy designation is a regulatory milestone that could accelerate path to approval for a first-in-class therapy addressing a large unmet need; no financial terms disclosed

regulatory timelineprobability of approval

Risk Factors

  • Breakthrough Therapy designation does not guarantee regulatory approval
  • Phase 3 results may not replicate Phase 1b/2a findings
  • Small market cap ($150M) implies high event sensitivity
  • No currently approved pharmacologic therapies for chronic SCI; commercial adoption uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3401443

Track record

19 reports on NGEN

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +51.65% at T+60 after the May 18, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $1.87 Now $1.82 −2.67% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 6/10 Viewing Entry $1.63 Now $1.82 +11.66% settles Nov 19
  4. Sep 25, 20267w ago 6-K Bearish 7/10 Entry $1.88 to $1.81 Now $1.82 +3.19% ▲ +3.72% +4.93% vs SPY
  5. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $1.88 to $1.81 Now $1.82 −3.19% ▼ −3.72% −4.93% vs SPY
  6. Sep 24, 20267w ago 6-K Neutral 3/10 Entry $2.02 to $1.76 Now $1.82 −9.90% ▼ −12.87% −12.46% vs SPY
  7. Aug 13, 202613w ago 6-K Neutral 5/10 Entry $1.76 to $1.76 Now $1.82 +3.41% · 0.00% +1.96% vs SPY
  8. Aug 13, 202613w ago Press Release Neutral 5/10 Entry $1.76 to $1.76 Now $1.82 +3.41% · 0.00% +1.96% vs SPY
  9. Jul 2, 202619w ago 6-K Bearish 5/10 Entry $2.12 to $1.86 Now $1.82 +14.15% ▲ +12.26% +13.19% vs SPY
  10. Jun 1, 202624w ago 6-K Bearish 6/10 Entry $2.00 to $1.81 Now $1.82 +9.00% ▲ +9.50% +6.54% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026